(Circulation. 1997;95:800-804.)
© 1997 American Heart Association, Inc.
Articles |
the Cardiology Division and Sealy Center for Molecular Cardiology (J.F.S., M.S.R.), University of Texas Medical Branch, Galveston; Medizinische Klinik III (Kardiologie) (C.B., P.M.), Heidelberg, Germany; Hematology-Oncology Division (S.R.H., A.B.K., L.A.H.), Department of Medicine, and Yerkes Regional Primate Research Center (A.B.K.), Emory University School of Medicine, Atlanta, Ga; and Cardiovascular Biology Laboratory (E.H.), Center for the Prevention of Cardiovascular Disease, Harvard University School of Public Health, Boston, Mass.
Correspondence to Marschall S. Runge, MD, PhD, Division of Cardiology, University of Texas Medical Branch, 301 University Blvd, Route 0553, Galveston, TX 77555-0553.
Background Inhibition of thrombin by either the indirect thrombin inhibitor heparin or by more potent direct thrombin inhibitors such as hirudin reduces thrombus formation after arterial injury. The present study was designed to determine if a fibrin-specific thrombin inhibitor could, by local thrombin inhibition, prevent thrombosis more effectively.
Methods and Results We first studied antithrombotic potency in vitro, comparing fibrin-targeted hirudin (recombinant hirudin covalently linked to the Fab' fragment of the anti-fibrin monoclonal antibody 59D8) to recombinant hirudin in baboon plasma. Fibrin-targeted hirudin was nine times more effective than recombinant hirudin in inhibiting fibrin deposition on experimental clot surfaces in baboon plasma (P<.01). The potency of fibrin-targeted hirudin was then compared with that of recombinant hirudin in a baboon model of thrombus formation. 111In-labeled platelet deposition was measured in a synthetic graft segment of an extracorporeal arteriovenous shunt in control animals and in animals receiving either fibrin-targeted hirudin or hirudin. In these experiments, fibrin-targeted hirudin was 10-fold more potent than hirudin in inhibiting platelet deposition and thrombus formation (P<.05).
Conclusions These data indicate that targeting a thrombin inhibitor such as hirudin to an epitope present in thrombi results in increased antithrombotic potency.
Key Words: antibodies thrombosis arteries
This article has been cited by other articles:
![]() |
P. Stoll, N. Bassler, C. E. Hagemeyer, S. U. Eisenhardt, Y. C. Chen, R. Schmidt, M. Schwarz, I. Ahrens, Y. Katagiri, B. Pannen, et al. Targeting Ligand-Induced Binding Sites on GPIIb/IIIa via Single-Chain Antibody Allows Effective Anticoagulation Without Bleeding Time Prolongation Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1206 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Peter, J. Graeber, S. Kipriyanov, M. Zewe-Welschof, M. S. Runge, W. Kubler, M. Little, and C. Bode Construction and Functional Evaluation of a Single-Chain Antibody Fusion Protein With Fibrin Targeting and Thrombin Inhibition After Activation by Factor Xa Circulation, March 14, 2000; 101(10): 1158 - 1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Soslau, R. Class, D. A. Morgan, C. Foster, S. T. Lord, P. Marchese, and Z. M. Ruggeri Unique Pathway of Thrombin-induced Platelet Aggregation Mediated by Glycoprotein Ib J. Biol. Chem., June 8, 2001; 276(24): 21173 - 21183. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |